Cholestasis and Pruritus

Clinical Presentation

• Pruritus is a characteristic symptom of cholestasis, affecting the majority of patients with cholestatic conditions, according to the American College of Obstetricians and Gynecologists 1, 2
• In intrahepatic cholestasis of pregnancy (ICP), pruritus is a defining characteristic that typically occurs in the second and third trimesters, as noted by the American College of Obstetricians and Gynecologists 1, 3
• The itch in cholestasis is often generalized but predominantly affects the palms and soles of the feet, and is typically worse at night, as reported by the American College of Obstetricians and Gynecologists 1, 3
• Unlike other pruritic conditions in pregnancy, cholestatic pruritus is generally not associated with a rash, though excoriations may develop due to scratching, according to the American College of Obstetricians and Gynecologists 1, 4
• In primary sclerosing cholangitis (PSC), pruritus affects the majority of patients and can dramatically impair quality of life, sometimes even leading to suicidal ideations in severe cases, as noted by the European Association for the Study of the Liver 2, 5

Epidemiology and Risk Factors

• In intrahepatic cholestasis of pregnancy, the incidence ranges from 0.3% to 15% in various populations, with most estimates between 0.3% to 0.5%, as reported by the American College of Obstetricians and Gynecologists 1

Management of Cholestatic Pruritus

• For intrahepatic cholestasis of pregnancy, ursodeoxycholic acid is recommended as first-line treatment for maternal symptoms, according to the American College of Obstetricians and Gynecologists 3
• In primary sclerosing cholangitis and other fibrosing cholangiopathies, bezafibrate or rifampicin are recommended as first-line pharmacological treatments for moderate to severe pruritus, as noted by the European Association for the Study of the Liver 2, 5
• Rifampicin (150-300 mg daily) has been considered effective but carries a risk of drug-induced hepatitis after 4-12 weeks in up to 12% of cholestatic patients, as reported by the European Association for the Study of the Liver 2, 6
• Non-pharmacological approaches include using emollients to prevent skin dryness, avoiding hot baths or showers, using cooling gels (e.g., menthol gels), and keeping nails short, as recommended by the European Association for the Study of the Liver 2, 7

Diagnostic Approach

• In patients with suspected cholestasis presenting with pruritus, measurement of serum bile acid and liver transaminase levels is recommended, according to the American College of Obstetricians and Gynecologists 3, 4
• A detailed history and physical examination are essential to differentiate cholestatic pruritus from other causes of pruritus without rash, as noted by the American College of Obstetricians and Gynecologists 1

Complications and Prognosis

• While cholestasis poses little risk to pregnant women, it confers significant risk to the fetus, including preterm delivery, meconium-stained amniotic fluid, and stillbirth, as reported by the American College of Obstetricians and Gynecologists 1, 3
• In most cases of intrahepatic cholestasis of pregnancy, the condition is self-limited and resolves after delivery, according to the American College of Obstetricians and Gynecologists 1

Treatment of Pruritus in Cholestasis

Initial Assessment and Non-Pharmacological Management

• Before initiating pharmacological therapy, exclude mechanical bile duct obstruction as the underlying cause of progressive pruritus, particularly in large duct cholestatic diseases like primary sclerosing cholangitis, and treat relevant strictures with endoscopic balloon dilation or stenting if necessary 8, 9
• All patients should implement non-pharmacological strategies, including using emollients to prevent skin dryness, avoiding hot baths or showers, and applying cooling gels to affected skin areas 8, 9

Pharmacological Treatment Algorithm

First-Line: Bezafibrate or Rifampicin

• Bezafibrate is the recommended first-line pharmacological treatment for moderate to severe cholestatic pruritus, with rifampicin as an alternative first-line option, based on the largest randomized controlled trial evidence from the FITCH trial 8, 9, 10
• Bezafibrate has a favorable safety profile, with no major side effects observed during short-term or long-term treatment, but requires monitoring for mild serum creatinine increases, myalgia, myopathies, and rarely elevated transaminases 10
• Rifampicin is an effective alternative first-line option, but may induce drug-induced hepatitis after 4-12 weeks in up to 12% of cholestatic patients 11, 10

Second-Line: Naltrexone

• If first-line agents fail or are not tolerated, the oral opioid antagonist naltrexone should be considered, starting at very low doses to avoid early side effects resembling opioid withdrawal syndrome 12, 11, 10

Third-Line: Sertraline

• Sertraline, a selective serotonin reuptake inhibitor, can be used as a third-line treatment, though data for sclerosing cholangitis-associated itch are insufficient 12, 11, 10

Quality of Life Impact

• Pruritus in cholestasis can dramatically impair quality of life, leading to sleep deprivation, loss of daytime concentration, auto-mutilation, and in severe cases, suicidal ideations, underscoring the importance of aggressive symptom management 8, 9

Treatment of Cholestatic Pruritus

First-Line Treatment

• The American Gastroenterological Association recommends cholestyramine as the first-line therapy for cholestatic pruritus due to its favorable safety profile 13, 14, 15
• Cholestyramine dosing should start with 4g daily and titrate up to 8-12g/day in divided doses, with administration timing at least 4 hours apart from ursodeoxycholic acid (UDCA) to prevent binding and loss of UDCA efficacy 13, 16
• The European Association for the Study of the Liver suggests that cholestyramine can be mixed with orange juice and refrigerated overnight to improve taste 13
• Common side effects of cholestyramine include constipation and gastrointestinal symptoms, which are the primary limitations 17

Second-Line Treatment

• The American Association for the Study of Liver Diseases recommends rifampicin as second-line therapy if cholestyramine fails or is not tolerated, with dosing starting at 150mg once to twice daily and titrating upward to 300-600mg/day based on symptoms and liver function monitoring 13, 14
• Rifampicin carries a risk of drug-induced hepatitis in up to 12% of cholestatic patients after 4-12 weeks of treatment, and liver function tests should be checked in 2-4 weeks after initiation 13, 16
• The National Institute of Diabetes and Digestive and Kidney Diseases advises to use rifampicin with particular care in advanced liver disease 13

Special Population: Intrahepatic Cholestasis of Pregnancy (ICP)

• The American College of Obstetricians and Gynecologists recommends ursodeoxycholic acid (UDCA) as the first-line treatment for maternal symptom relief in pregnant women with cholestatic pruritus, with dosing starting at 10-15mg/kg/day divided into 2-3 doses 17
• UDCA typically decreases pruritus within 1-2 weeks, and dose adjustment can be made if pruritus is not relieved, up to a maximum of 21mg/kg/day 17

Refractory Cases and Advanced Interventions

• The European Association for the Study of the Liver suggests that liver transplantation is highly effective for intractable pruritus, with rapid reduction in severity often within 24 hours, and pruritus that is "persistent and intractable" after therapeutic trials is an indication for transplantation 13, 14, 15